- Home
- ACLX vs VRNS Comparison
ACLX vs VRNS Comparison
Compare ACLX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- VRNS
- Stock Information
- Founded
- ACLX 2015
- VRNS 2004
- Country
- ACLX United States
- VRNS United States
- Employees
- ACLX N/A
- VRNS N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- VRNS Computer Software: Prepackaged Software
- Sector
- ACLX Health Care
- VRNS Technology
- Exchange
- ACLX Nasdaq
- VRNS Nasdaq
- Market Cap
- ACLX 4.4B
- VRNS 4.0B
- IPO Year
- ACLX 2022
- VRNS 2014
- Fundamental
- Price
- ACLX $90.01
- VRNS $33.68
- Analyst Decision
- ACLX Strong Buy
- VRNS Strong Buy
- Analyst Count
- ACLX 8
- VRNS 19
- Target Price
- ACLX $115.50
- VRNS $60.68
- AVG Volume (30 Days)
- ACLX 427.8K
- VRNS 3.9M
- Earning Date
- ACLX 11-05-2025
- VRNS 10-28-2025
- Dividend Yield
- ACLX N/A
- VRNS N/A
- EPS Growth
- ACLX N/A
- VRNS N/A
- EPS
- ACLX N/A
- VRNS N/A
- Revenue
- ACLX $35,898,000.00
- VRNS $608,677,000.00
- Revenue This Year
- ACLX N/A
- VRNS $14.75
- Revenue Next Year
- ACLX $220.95
- VRNS $16.12
- P/E Ratio
- ACLX N/A
- VRNS N/A
- Revenue Growth
- ACLX N/A
- VRNS 11.37
- 52 Week Low
- ACLX $47.86
- VRNS $32.02
- 52 Week High
- ACLX $100.34
- VRNS $63.90
- Technical
- Relative Strength Index (RSI)
- ACLX 57.21
- VRNS 24.28
- Support Level
- ACLX $85.00
- VRNS $33.07
- Resistance Level
- ACLX $91.68
- VRNS $36.34
- Average True Range (ATR)
- ACLX 4.14
- VRNS 1.98
- MACD
- ACLX -0.08
- VRNS -0.50
- Stochastic Oscillator
- ACLX 71.76
- VRNS 5.00
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.